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Background/Purpose: This study aims to study the factors that affect the stamina of elderly patients
during trospium treatment.
Methods: To carry out the experiment, 843 men and women older than 60 years (average age, 68.4 years)
who had been taking trospium for 12 months were selected. The questionnaire survey on demographic
and social status, ﬁnancial statement analysis, academic certiﬁcates, Overactive bladder Questionnaire
short form and Medical Outcomes Study-Short Form questionnaires, bladder diaries, and uroﬂowmetry
were used for studies of adherence to treatment.
Results: The average time of reaching the 30-day trospium-treatment-free period (compliance “survival
rate”) was 191 days. The percentage of patients who remained compliant for 6 months and 1 year were
58.3% and 44.0%, respectively. According to our data, the percentage of highly educated (59.3%), married
(63.8%), and city (70.6%) residents who are aware of the nature of their disease (77.5%) are signiﬁcantly
higher in the cohort of consistent patients; yet the percentage of caffeine abusers is lower (10.9%). In this
cohort, the percentage of income spent on trospium purchase (3.1%) was lower, but income and payment
level for medical expenses were higher (p  0.05 and p  0.01, respectively, compared with other co-
horts). An analysis of regressive models of changes in squared percentage of income and trospium costs
has conﬁrmed the hypothesis of the impact of these factors on treatment compliance. In the cohort of
consistent patients, the average number of points of role physical, social functioning, role emotional, and
mental health values that describe the health impact on the quality of life turned out to be signiﬁcantly
higher. Severe incontinence symptoms (70.8%) and overactive bladder (35.9%) prevailed among patients
of this cohort, which were also associated with high treatment efﬁcacy and a signiﬁcantly lower number
of side effects (9.3%).
Conclusion: High trospium treatment compliance among elderly men and women is determined by
several uneven demographic, social, economic, and medical factors.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).ces, School of Humanities, Far
, Ajax 10, Corp. F, Ofﬁce 733,
ration.
inical Gerontology & Geriatrics. Pub
d/4.0/).1. Introduction
The morbidity of lower urinary tract symptoms (LUTS),
including overactive bladder (OAB) symptoms, among people is
very high. LUTS have, at least occasionally, been reported in
26e33% of men and 27e46% of women of all races.1 LUTS is known
to have an adverse impact on the health-related quality of life.2,3
Besides, the signiﬁcant prevalence of LUTS is due to its high eco-
nomic costs.4,5lished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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to comprise antimuscarinic (AM) drugs. Among AM drugs,
trospium chloride, a quaternary ammonium compound that
neither penetrates the bloodebrain barrier nor affects the central
nervous system, has been widely used. It allows the avoidance of
adverse side effects and increases demand for trospium during
treatment of various forms of LUTS, particularly among elderly
persons.6,7
However, when studying the efﬁcacy and safety of various
trospium dosages among elderly patients who suffered from
different forms of LUTS in our previous experiments, we noticed
poor patient compliance with treatment. Moreover, on adherence
affect not only medical factors.8,9 According to most researchers,
absence of results, side effects, and dosage regimen are attribut-
able to medical factors that cause low compliance.10e12 Yet some
researchers point to polymorbidity, poor awareness of patients,
and some other factors as important factors that contribute to the
loss of compliance.13,14 A number of researchers cast reasonable
doubt on the fact that pharmacological properties of various AM
drugs affect treatment compliance level.15 However, the issue of
balance of various factors' impact on patient compliance to ther-
apy with AM drugs, particularly trospium chloride, has been
studied incompletely. Most of the available studies have been
carried out in a retrospective way, without any correlation be-
tween trospium intake, a particular diagnosis, and diagnosis
veriﬁcation by special methods. Given these circumstances, in this
experiment, we set the goal of studying heterogeneous factors
that affect the stamina of elderly patients who suffer from
different forms of LUTS during trospium chloride treatment to
increase the manageability of OAB symptoms.
2. Methods
2.1. General information
A randomized blind prospective study on factors affecting the
stamina of older patients during their trospium treatment was
carried out from January 4, 2012 to January 6, 2014 at the Regional
Clinical Diagnosis Center, City Outpatient Hospital Number 3, and a
geriatric hospital located in Vladivostok City, Russia. A total of 843
patients (449 women and 394 men; age range, 60e87 years)
participated in the experiment. The average age was 68.4 years. To
“blind” the research team dealing with statistical analysis of ob-
tained data arrays, data ﬁles were impersonalized by assigning
random numbers and personal data were deleted. Stratiﬁed
randomization allowed a roughly even representation of men and
women during patient selection.
Scope of selection was calculated with reference to conﬁdence
probability of 95% and conﬁdence interval of ±5%.
2.2. Inclusion/exclusion criteria and factors of the studies
Persons who visited an urologist on odd days of the months and
were prescribed a standard dosage of trospium chloride (5e15 mg
twice a day) as monotherapy for a prolonged period by the urolo-
gist were included in the studied group. The inclusion criterionwas
the presence of any of the following diagnoses: OAB (N32.81), urge
incontinence (N39.41), mixed incontinence (N39.46), and nocturia
(R35.1).16
The examination of cognitive function was conducted at the
start of the study using the Montreal Scale. If a patient gained < 20
points, he/she was excluded from participation in the experiment.
In the course of the experiment, changes in the condition of
patients' lower urinary tract were controlled with the use of
overactive bladder questionnaire short form (OABq-SF) anduroﬂowmetry (at the start and 1st and 2nd control points), and also
bladder diaries that were ﬁlled in on a daily basis.17 Columns for
ﬁlling in information about down-lying time, time of falling asleep,
time of awakening due to the desire to urinate, amounts of
consumed liquid, caffeine, alcohol, and smoked cigarettes, and the
time of trospium intake were added to bladder diaries. We
considered three or more episodes of urinary incontinence a day as
evidence of LUTS severity.18 At the start of the study, all participants
were made aware of and given adequate information on the nature
of dysfunction of accumulation and urine evacuation in LUTS,
trospium's mechanism of action on the body, as well as its dosage
regimen. A total of 441 (52.3%) patients used this option. At the end
of the experiment, a comparative analysis of percentages of
informed patients among groups with different compliance levels
was conducted.
Besides, factors such as Charlson Comorbidity Index.19 forms of
associated diseases, number of used dosage forms, and awareness
of LUTS therapy methods14,20 were studied using the analysis of
individual outpatient medical records of patients and questionnaire
surveys.
A study on demographic, social, and economic properties was
carried out using a questionnaire survey, a ﬁnancial statement
analysis (certiﬁcate of income issued by tax ofﬁce), and copies of
academic certiﬁcates.
Annual income and average monthly income; average relation
between pension and living wage; monthly costs of trospium and
other drugs, as well as their squared values; and percentages of
such costs in total patient costs and their squared values were
considered as social and economic factors. Percentages of persons
with an income level below the living wage, and those dealing with
physically demanding jobs and exposed to hazardous conditions
during their labor activities were calculated.21 Levels of income and
expenses are shown with reference to inﬂation against the United
States dollar value as of April 2012.
Exclusion criteria were the presence of oncological diseases in
their end stages, intake of AM drugs 6 months prior to the start of
this study, and the status of being employed.
2.3. Compliance and stamina estimation
A trospium-treatment-free period of 30 days during the obser-
vation period was considered as a patient stamina criterion. The
level of stamina and compliancewere separately calculated for each
potential factor affecting patient behavior. The average level of
patient stamina was deﬁned as the percentage of days, in obser-
vation period, during which the patient was acting in accordance
with the recommendations of the attending physician. To compare
the impacts of heterogeneous factors on treatment compliance,
patients were split into three basic cohorts: consistent members
(compliance rate of  80%), moderately consistent members (
50e<80%), and poorly consistent members (< 50%).22
2.4. Statistical analysis
A 30-day treatment-free period expectation model was used for
the estimation of compliance level. To create this model, three-
parameter Weibull distribution accompanied by ﬁrst-type double
right censoring (relevant to the 1st and 2nd control points) was used.
Adjustment of distribution to actual data was carried out using the
HollandereProschan criterion.
The impacts of demographic, social, economic, and medical
factors stipulated in Clause 2.2 were estimated during the analysis
of models with simple gamma distribution and a log-link function.
The important factor of control for persons with different compli-
ance levels was carried out separately, with further comparison of
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variables was carried out using two-parameter regression models.
In a number of cases, the Spearmen rank correlation coefﬁcient was
calculated for determining the degree of correlation between
changes in parameters.
Differences were considered as signiﬁcant at р < 0.05, while all p
values were two sided.
All statistical analyses were performed using SAS version 8.0.2
(SAS Institute Inc., Cary, NC, USA).
2.5. Ethical principles
When creating and implementing experimental design, our
research group followed the principles of the Declaration of Hel-
sinki. All the participants of the experiment submitted written
informed consent to participation. The research protocol was
approved by the local ethics committee prior to the experiment.
3. Results
After 3months, 66.5% and 44.0% of patients remained compliant
with trospium treatment for 6 months and 1 year, respectively. The
average time of reaching the 30-day trospium-treatment-free
period was 191 days. Mild cognitive impairments were noted in
19.1% of patients before the start of the experiment (average points,
24.3 ± 2.7). The number of the Montreal Scale points scored by the
other patients met the norm. The average points for the entire
sample were 27.7 ± 2.9.
The percentage of married persons who stay within the city
municipal district and have high educational qualiﬁcation turned
out to be signiﬁcantly higher in the cohort of consistent patients (a
signiﬁcant difference of  0.05 for all cases; Table 1).
The total annual income and costs of medical services in the
cohort of patients with a high compliance rate turned out to be
signiﬁcantly higher than those in the other cohorts. The average
monthly income and auxiliary income level differed in groups of
minimum and maximum stamina (p  0.05 and p  0.01, respec-
tively). Other parameters were statistically close between cohorts
(Table 2).
The compliance rate was substantially higher among patients
with higher income and those spending a small share of income on
trospium costs. Impact of income level (p < 0.05) and its squared
value (p < 0.01) in the regressionmodel was statistically signiﬁcant.
The impact of both the percentage of trospium costs and the
squared value of such costs on the compliance rate in the regressionTable 1
Sociodemographic characteristics of persons 60 years of age receiving trospium (n ¼ 8
Parameters Level of adh
<50% (n ¼ 253) 50e<80% (
Mean or N SD or % Mean or N
Age 73.7 8.5 71.2
Female 142 56.1 141
Married 101 39.9 127
Not married 152 60.1 151
Family members living together 1.8 0.4 2.1
Number of children 1.4 0.4 1.7
Lives in the city district 119 47.0 154
Lives in rural areas 134 53.0 124
Level of education
Higher (university) 92 36.5 107
Secondary general 77 30.4 89
Secondary professional 84 33.2 82
SD ¼ standard deviation.
Bold emphasizes the signiﬁcance of the differences.model was also substantial (p < 0.01 and p < 0.01, respectively). The
impact of income level was substantially higher among elderly
persons suffering from urge incontinence (27.8e35.5%) and OAB
(31.2e39.4%) than among people with other diagnoses (Figure 1).
In the cohort of stable patients, the number of caffeine abusers
was signiﬁcantly low (p  0.01). In the same cohort, the percentage
of individuals informed about the nature of the disease and the
impact of trospium on the body was signiﬁcantly higher (77.5%)
than that in the other groups (p  0.01 and p  0.01, respectively;
Table 3).
The average number of points of role physical (RР), social
functioning (SF), role emotional (RE), and mental health (MH)
values among persons with a high compliance rate at control points
turned out to be signiﬁcantly higher than that at the start of the
study.
In the course of the experiment, it was found that in 69.4% of
individuals with long-term treatment of trospium, some form of
urinary incontinence was veriﬁed (OAB at 30.6%; Table 4). An
analysis conducted after the end of the experiment showed that the
percentage of compliance was signiﬁcantly higher among in-
dividuals diagnosed with OAB. The result of comparison of
compliant patient percentages in the subgroups with other di-
agnoses was statistically homogeneous.
Severe inconsistence symptoms prevailed among consistent
patients (70.8%).
According to the OAB-SF questionnaire data, the average
number of points assigned during the estimation of urgency and
nighttime urination at the end of the experiment signiﬁcantly
differs between cohorts of consistent and inconsistent patients
(p  0.05). The average number of points assigned during the
estimation of urinary inconsistence episodes among consistent
patients turned out to be signiﬁcantly smaller than that in the
cohort of poorly consistent (p  0.01) as well as moderately
consistent (p  0.05) patients. Similar changes were detected
during the estimation of urodynamic condition with the use of
bladder diaries. The average urine volume ﬂow rate among
consistent patients turned out to be signiﬁcantly higher than that
among the patients of other cohorts (p  0.05), while the average
bladder volume at the end substantially exceeded the bladder
volume of inconsistent (p  0.01) and moderately consistent
(p  0.05) patients (Table 5).
In total, 124 patients (14.7%) involved in the study discontinued
their participation due to intolerable side effects. Of these, 14
(1.7%) were from the group with the highest compliance level, 54
(6.4%) from the group with middle compliance, and 56 (6.6%) from43).
erence p
n ¼ 278) 80% (n ¼ 312)
SD or % Mean or N SD or % p1/2 p2/3 p1/3
6.2 67.1 8.2 0.05 0.05 0.05
50.3 166 53.2 0.05 0.05 0.05
45.7 199 63.8 0.05 ≤0.05 ≤0.05
54.3 113 36.2 0.05 ≤0.05 ≤0.05
0.6 2.0 0.9 0.05 0.05 0.05
0.8 1.6 1.0 0.05 0.05 0.05
55.4 237 76.0 0.05 ≤0.05 ≤0.05
44.6 75 24.0 0.05 ≤0.05 ≤0.05
38.5 185 59.3 0.05 ≤0.05 ≤0.05
32.0 77 24.7 0.05 0.05 0.05
29.5 50 16.0 0.05 ≤0.05 ≤0.05
Table 2
Quantitative comparison of the economic characteristics of persons 60 years of age receiving trospium (n ¼ 843).a
Characteristics Adherence Mean difference p
<50% (n ¼ 253) 50e80% (n ¼ 278) 80% (n ¼ 312)
Adjusted
mean, $ or
rate (%)
Adjusted
standard
error
Median Adjusted
mean, $ or
rate (%)
Adjusted
standard
error
Median Adjusted
mean, $ or
rate (%)
Adjusted
standard
error
Median p1/2 p2/3 p1/3 p1/2 p2/3 p1/3
Annual income $3117 $261 $2,761 $3,316 $289 $3,115 $3,891 $318 $3559 $259 $575 $774 0.05 ≤0.05 ≤0.01
Average monthly income $259.7 $21.7 $230.1 $276.3 $24.1 $259.5 $324.2 $26.5 $296.6 $16.6 $47.9 $64.5 0.05 0.05 ≤0.05
Annual additional income $119.7 $20.1 $98.2 $217.4 $26.6 $188.3 $293.2 $34.6 $258.8 $97.7 $75.8 $173.5 0.05 0.05 ≤0.01
Annual medical cost $579.6 $56.0 $522.7 $599.6 $37.6 $559.1 $702.4 $42.8 $673.7 $20.0 $102.8 $122.8 0.05 ≤0.05 ≤0.05
Annual prescription
drug cost
$247.5 $31.6 $221.7 $249.0 $46.7 $213.5 $317.7 $57.8 $291.7 $1.5 $68.7 $70.2 0.05 0.05 0.05
Annual expense on
trospium
125.7 12.8 123.6 121.3 23.1 121.9 127.6 11.9 120.6 $4.4 $6.3 $1.9 0.05 0.05 0.05
Annual expense on other
drags
419.5 35.1 371.8 450.2 52.8 425.6 465.7 48.8 418.8 $30.7 $15.5 $46.2 0.05 0.05 0.05
Short-term disability days 5.3 1.4 d 4.6 0.7 d 5.9 0.8 d 0.9 1.3 0.6 0.05 0.05 0.05
Long-term disability days 6.1 0.9 d 7.1 1.7 d 5.2 1.6 d 1.0 1.9 0.9 0.05 0.05 0.05
Bold emphasizes the signiﬁcance of the differences.
a Income information is missing for two persons with <50% adherence, 10 persons with 50%e<80% adherence, and two patients with 80% adherence.
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Figure 1. Dependence between percentage of days of implementing trospium intake instructions and annual income, and also share of trospium cost in the monthly income of
elderly persons who participated in the experiment (n ¼ 843).
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was noted in 59 patients (7.0%), and in the group of treatment-
compliant patients, it was identiﬁed only in ﬁve cases (0.6%).
“Vomiting” symptom was found to have the second highest fre-
quency of occurrence; it was noted in 27 patients (3.2%). Symp-
toms such as blurred vision, constipation, rash, dry skin, and
others were noted in 54 patients (6.4%). Nine percent of patients of
the cohort comprising those with a medium compliance rate and
11.5% of those comprising poorly consistent patients mentioned
intolerable dry mouth as the reason to decline further treatment.
In the cohort of stable patients, the percentage of individuals
refusing treatment because of intolerable side effects appeared to
be the lowest.4. Discussion
A signiﬁcant prevalence of married and highly educated patients
who stay in cities, and have high annual income and costs of
medical services was detected in the cohort of highly compliant
persons. Calculation of regressive inﬂuence models could deter-
mine the substantial impact of income levels and their squared
values, and also percentages of income and its squared values,
which patients spend on trospium purchase, on treatment
compliance.
The percentage of consistent patients who are aware of the
nature of the disease and its treatment methods turned out to be
substantially higher than that in other cohorts, while the
Table 3
Descriptive characteristics related to health of persons taking trospium (n ¼ 843).
Descriptive characteristics Level of adherence p
<50% (n ¼ 253) 50e<80% (n ¼ 278) 80% (n ¼ 312)
Mean or N SD or % Mean or N SD or % Mean or N SD or % p1/2 p2/3 p1/3
Charlson Comorbidity Index 8.1 1.5 11.5 3.1 9.7 2.7 0.05 0.05 0.05
Bad habits
Alcohol abuse 21 8.3 15 5.4 19 6.1 0.05 0.05 0.05
Smoking 98 38.7 132 47.5 134 42.9 0.05 0.05 0.05
Caffeine abuse 91 36.0 118 42.4 34 10.9 0.05 ≤0.01 ≤0.01
Awareness of treatment options 102 40.3 97 34.9 242 77.5 0.05 ≤0.01 ≤0.01
Unsatisfactory experience in treating other AM drugs 201 79.4 235 84.5 239 76.6 0.05 0.05 0.05
Taking medication to treat comorbidities 213 84.1 267 96.0 293 93.9 0.05 0.05 0.05
Observance of sleepewake cycle 223 88.1 257 92.4 260 83.3 0.05 0.05 0.05
AM ¼ antimuscarinic; SD ¼ standard deviation.
Bold emphasizes the signiﬁcance of the differences.
Table 4
Medical characteristics of persons taking trospium (n ¼ 843).a
Level of adherence p
<50% (n ¼ 253) 50e<80% (n ¼ 278) 80% (n ¼ 312)
N % N % N % p1/2 p2/3 p1/3
Diagnoses
OAB, n ¼ 258 (30.6%) 57 22.5 89 32.0 112 35.9 0.05 0.05 ≤0.05
Urge UI, n ¼ 285 (33.8%) 79 31.2 121 43.5 85 27.2 0.05 ≤0.05 0.05
Mixed UI, n ¼ 144 (17.1%) 49 19.4 32 11.5 63 20.2 0.05 0.05 0.05
Nocturnal UI, n ¼ 156 (18.5%) 68 26.9 36 12.9 52 16.7 0.05 0.05 0.05
Severity of symptoms and efﬁcacy of treatment
Severe symptoms (EUI  3/d) 47 18.5 82 29.4 221 70.8 0.05 ≤0.01 ≤0.01
Efﬁcacy of treatment (1 CP, n ¼ 492)b 45 50.5 142 83.0 217 93.5 ≤0.01 0.05 ≤0.01
Efﬁcacy of treatment (2 CP, n ¼ 371) 34 54.8 93 90.3 191 92.7 ≤0.01 0.05 ≤0.01
CP ¼ check point; EUI ¼ episodes of urge incontinence; OAB ¼ overactive bladder; SD ¼ standard deviation; UI ¼urination incontinence.
Bold emphasizes the signiﬁcance of the differences.
a Total percentage of urge, mixed, and nocturnal incontinence, and OAB in total exceeds 100% due to the fact that a combination of these diseases may occur in one person.
b Efﬁcacy of treatment indicates the number of patients with a score of  8 according to OABqeSF (overactive bladder questionnaire short form) and normal uroﬂowmetry
results after the 6th month (1 checkpoint; N ¼ 492) and 12th month (2 checkpoints; N ¼ 371) of observation.
Table 5
Change in the status of the lower urinary tract during the experiment for persons taking trospium (n ¼ 843).a
Parameters Level of adherence p p
<50% (n ¼ 253; 62) 50e<80% (n ¼ 278; 103) 80% (n ¼ 312; 206)
Start Finish Start Finish Start Finish Start Finish
p1/2 p2/3 p1/3 p1/2 p2/3 p1/3
Assessment of the state of LUT of OAB-SF questionnaire [scores, (SD)]
Daytime urination 4.1 (1.1) 2.5 (1.3) 4.2 (1.0) 2.7 (1.0) 3.6 (1.4) 1.0 (0.8)* 0.05 0.05 0.05 0.05 0.05 0.05
Night urination 4.5 (0.8) 2.3 (1.7) 4.6 (1.5) 2.8 (1.6) 3.9 (1.3) 0.7 (0.5)** 0.05 0.05 0.05 0.05 0.05 ≤0.05
Urgency 4.5 (1.2) 4.0 (1.3) 4.2 (1.2) 2.6 (1.2) 4.4 (1.3) 1.1(0.7)** 0.05 0.05 0.05 0.05 0.05 ≤0.05
Urge incontinence 4.2 (1.3) 3.3 (0.6) 4.3 (1.1) 3.7(1.3) 4.5 (1.2) 1.0 (0.6)** 0.05 0.05 0.05 0.05 ≤0.05 ≤0.01
Assessment of the state of LUT of diaries of urination [episodes per day (SD)]
Daytime frequency 9.8 (1.9) 8.0 (1.5) 10.4 (2.0) 7.5 (1.6) 10.8 (1.6) 5.6 (1.2)* 0.05 0.05 0.05 0.05 0.05 0.05
Night frequency 2.3 (0.7) 2.3 (1.1) 2.7 (0.9) 1.9 (0.5) 2.4 (0.4) 0.6 (0.4)* 0.05 0.05 0.05 0.05 ≤0.05 ≤0.05
Urgency 7.8 (1.8) 6.1 (1.3) 7.1 (2.1) 4.2 (0.7) 6.9(1.3) 1.5 (1.0)* 0.05 0.05 0.05 0.05 ≤0.05 ≤0.01
Urge Incontinence 3.0 (1.4) 3.1 (0.6) 3.4 (0.9) 1.5 (1.0) 3.9 (0.8) 1.3 (0.7)** 0.05 0.05 0.05 0.05 ≤0.05 ≤0.05
Assessment of the state of LUT of urodynamic parameters (uroﬂowmetry)
Qaver, mL/s (SD) 15.1 (3.6) 17.5 (2.4) 13.9 (3.2) 17.0 (2.3) 13.5 (4.4) 23.1 (2.2)** 0.05 0.05 0.05 0.05 ≤0.05 ≤0.05
Qmax, mL/s (SD) 18.1 (3.7) 19.1 (2.0) 19.0 (4.8) 24.1 (4.2) 18.6 (4.3) 26.1 (6.7) 0.05 0.05 0.05 0.05 0.05 0.05
Bladder volume, mL 181.3 (37.6) 190.6 (26.7) 176.8 (29.4) 272.3(27.5) 169.4 (27.4) 341.9 (30.6)* 0.05 0.05 0.05 ≤0.05 ≤0.05 ≤0.01
*p  0.05.
**p  0.01.
LUT¼ lower urinary tract; OABq-SF¼ overactive bladder questionnaire short form; Qaver ¼ average ﬂow rate; Qmax¼maximum ﬂow rate; SD¼ standard deviation (indicated
in parentheses).
Bold emphasizes the signiﬁcance of the differences.
a Bladder volume indicates the bladder volume at the ﬁrst desire to void (mL).
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Signiﬁcant increases in points of RР, SF, RE, and MH values that
describe health inﬂuence on the quality of life were reported for
persons compliant with the treatment. The most widespreaddiagnosis among consistent and moderately consistent patients
turned out to be OAB (35.9%) and urge incontinence (43.5%),
respectively. Persons who suffer from severe urinary inconsis-
tence symptoms (70.8%) signiﬁcantly prevailed in the cohort with
K.V. Kosilov et al. / Journal of Clinical Gerontology & Geriatrics 7 (2016) 124e130 129treatment compliance of  80%. High treatment efﬁcacy was re-
ported in cohorts of consistent and moderately consistent
patients.
Thus, in general, our results correlate well with the data of other
researchers. One study indicated that the average time prior to
rejection of treatment with AM drugs is 159 days.23 In our study on
the duration of trospium intake, this value was 191 days, which
could probably be explained by some of its pharmacological effects,
particularly the absence of any adverse impact on the central ner-
vous system and high effect selectivity. These assumptions are
conﬁrmed by the data of other research groups on higher level of
trospium treatment compliance among persons of different age
strata.24
There are singular reports regarding side effects and poor results
as the main reasons for treatment rejection in the relevant litera-
ture10,11; yet they correlate neither with our results nor with most
researchers' point of view. According to our data, only 14.5% of
patients in the whole scope of selection rejected trospium treat-
ment or interrupted it due to intolerable side effects, with similar
percentages being reported by many other researchers.24e26 There
are virtually no data on the dependence between severity of
symptoms and forms of disorders in available studies. Meanwhile it
is reported that the patients with severe symptoms have a high
adherence to receive medication. It could be due to abrupt wors-
ening of the quality of life related to the health of such patients. It is
also conﬁrmed by substantial changes in RР, SF, RE, and MH values
among patients with high level of compliance during the course of
treatment. The impact of an excessive amount of caffeine on the
emergence of OAB symptoms is considered to have been studied;
yet we have established that moderate caffeine consumption is a
factor that correlates with high level adherence of trospium
treatment.
When analyzing the impacts of comorbidity and taking of
other medicinal products on trospium treatment compliance, we
obtained results that were somewhat different from the data of
other researchers. There is information that polymorbidity is able
to cause supporting effect to the compliance of taking medicinal
products, as it often involves taking multiple medications.10 It can
be assumed that taking of some of these products is directly
related to the current state of health and acts as an incentive
reminder to take an entire pool of drugs. According to other
sources of information, in polypharmacy, many patients tend to
ignore a part of the prescribed medications, reducing an exces-
sive medication load at their own discretion.13 The protocol of our
study had no clause on a special study of polypharmacy as a
predictor of compliance (e.g., level of compliance with different
numbers of drugs). However, according to our data, the per-
centage of patients with multiple diseases who took several
medicines was proved to be very high in all three groups with
different levels of trospium treatment compliance (84.1e96.0%).
This is probably due to the fact that, with an average age of
67.1e73.7 years, most patients in the groups had a high preva-
lence of polymorbidity and some other reasons for refusal, for
instance, ﬁnancial difﬁculties or excessively critical attitude to
minor side effects. Certainly, we are aware that this information
is insufﬁcient for rational conclusions, and the matter requires
further investigation.
In our study, we have made an attempt to compare the impor-
tance of heterogeneous factors for drawing behavioral decision by
patients who take trospium for a long period of time to treat
various forms of LUTS. We have been observing a substantial vol-
ume of patients throughout a year, which allowed us to analyze and
compare the levels of demographic, social, economic, and medical
compliance-related factors. In our opinion, the obtained results
could be used for practical healthcare when analyzingappropriateness of trospium prescription to patients with different
social, economic, and medical properties.
5. Conclusions
This prospective randomized study has shown that the impact
of various medical, social, demographic, and economic factors on
trospium treatment compliance among patients over 60 years is
uneven. The average time of reaching the 30-day trospium-
treatment-free period was 191 days. The percentages of patients
who remained compliant for 6 months and 1 year were 58.3% and
44.0%, respectively.
Highly educated city dwellers who are married, have compar-
atively high annual/monthly income and costs of medical services,
and spend a small percentage of income monthly trospium costs
prevailed in the cohort of consistent patients. Consistent patients
were better aware of the nature of their disease and were not
caffeine abusers; they also showed substantial positive changes in
health condition indices such as RР, SF, RE, and MH values at the
end of the experiment. Among patients who were committed to
treatment to have the largest percentage suffering from OAB, se-
vere urinary inconsistence symptoms, and high treatment efﬁcacy,
which was conﬁrmed by changes in urodynamic values, while
signiﬁcantly smaller percentage of side effects compared with
other cohorts was reported.
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